SCHEMBL23704878

SCHEMBL23704878

CC1(c2cccc(Br)c2)CC(=O)C1(Cl)Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA1 P02708 1/20 0.40
▸ CHRNG P07510 1/20 0.40
▸ CHRNB1 P11230 1/20 0.40
▸ CHRNB2 P17787 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ CHRNB4 P30926 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ CHRNA3 P32297 1/20 0.40
▸ CHRNA4 P43681 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ CHRND Q07001 1/20 0.40
▸ HCAR3 P49019 1/20 0.40
▸ HCAR2 Q8TDS4 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ HSD11B1 P28845 2/20 0.36
▸ UTS2R Q9UKP6 1/20 0.36
▸ BACE1 P56817 2/20 0.36
▸ CTSD P07339 1/20 0.36
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23715110 0.87 HCAR3 (0.40) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL23705409 0.73 HCAR3 (0.43) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL23715111 0.70 CHRNA1 (0.45) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL9158624 0.69 ALDH1A1 (0.38) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL9918032 0.67 OPRD1 (0.44) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL3647973 0.67 CHRNA1 (0.48) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL362252 0.67 CHRNA1 (0.42) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL1173493 0.67 CHRNA1 (0.42) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL1173469 0.67 CHRNA1 (0.42) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL8122310 0.66 MEN1 (0.38) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 — — CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 — — EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CHRNA1 4253/4885CHRNG 4704/4885CHRNB1 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback